Principal Investigator(s):
Objective:This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose.Last updated September 15, 2022
Prevention Option(s):HIV Vaccine
Study Design:Placebo-controlled, Randomized
Official Code: NCT04725877
Trial Sponsors: Gates Foundation
Start Date
End Date
December 28, 2020
January 1, 2025
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women